Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.48 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4540345 | 0.89 | ERBB2 (0.62) | EGFRERBB2KCNH2 | |
| SCHEMBL4385684 | 0.82 | ERBB2 (0.56) | EGFRERBB2KDRKCNH2EPHA2 | |
| SCHEMBL5486484 | 0.80 | ERBB2 (0.54) | EGFRERBB2SRCKCNH2 | |
| SCHEMBL5477568 | 0.80 | ERBB2 (0.54) | EGFRERBB2KDRKCNH2EPHA2 | |
| SCHEMBL5469740 | 0.79 | ERBB2 (0.46) | EGFRERBB2SRCKDRKCNH2 | |
| SCHEMBL4391670 | 0.77 | ERBB2 (0.79) | EGFRERBB2KCNH2 | |
| SCHEMBL4396239 | 0.77 | ERBB2 (0.79) | EGFRERBB2KCNH2 | |
| SCHEMBL4385333 | 0.77 | ERBB2 (0.79) | EGFRERBB2KCNH2 | |
| SCHEMBL4388273 | 0.76 | ERBB2 (0.63) | EGFRERBB2KCNH2 | |
| SCHEMBL4397170 | 0.76 | ERBB2 (0.63) | EGFRERBB2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ABL1, EGFR | EGFR 3/4885ERBB2 1/4885SRC 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.